查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1971523

非銀抗菌敷料市場 - 全球產業規模、佔有率、趨勢、機會、預測、區域及競爭格局（2021-2031）

Non-Silver Antimicrobial Dressings Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球非銀抗菌敷料市場預計將從 2025 年的 4.9455 億美元成長到 2031 年的 6.2975 億美元，複合年成長率為 4.11%。

這些先進的創傷護理方案利用碘、蜂蜜、聚六亞甲基雙胍 (PHMB) 和氯己定等替代性消毒劑來控制感染和微生物附著量，而無需依賴銀。推動這一成長的主要因素是慢性病（尤其是糖尿病和血管疾病）在全球範圍內的日益流行，這些疾病導致難治性潰瘍的發生率增加，而這些潰瘍需要有效的感染控制。此外，臨床上對銀的抗藥性和細胞毒性的擔憂也促使人們採用這些非銀替代品。例如，國際糖尿病聯盟 (IDF) 報告稱，到 2024 年，全球將有約 5.89 億成年人患有糖尿病，這是一個龐大的患者群體，需要可靠的抗菌干預措施。

市場概覽
預測期 2027-2031
市場規模：2025年 4.9455億美元
市場規模：2031年 6.2975億美元
複合年成長率：2026-2031年 4.11%
成長最快的細分市場
最大的市場 北美洲

儘管市場需求強勁，但由於嚴格的法規結構和不穩定的報銷環境，該市場面臨許多障礙。製造商必須應對複雜的核准流程，該流程要求提供大量的臨床證據，以證明這些替代療法符合既定標準的安全性和有效性。此外，公共醫療系統的預算限制往往限制了這些先進治療方法的應用，迫使醫療服務提供者依賴成本較低的傳統敷料。這種經濟障礙阻礙了成本敏感地區的推廣，從而限制了全球非銀抗菌敷料市場的整體成長潛力。

市場促進因素

由於老化與慢性傷口風險之間存在密切聯繫，全球老年人口的快速成長是推動非銀抗菌敷料普及的主要動力。隨著老齡化，生理機能會逐漸衰退，例如皮膚彈性下降和免疫反應減弱，這顯著增加了褥瘡和靜脈性腿部潰瘍等難治性疾病的風險。這些慢性問題通常需要長期感染控制，而醫用蜂蜜和聚羥基丁酸酯（PHMB）等替代製劑往往比銀基產品更受歡迎，以避免細胞毒性和抗藥性問題。聯合國人口基金（UNFPA）2024年6月發布的《老化》報告也印證了這項人口結構變化，報告指出，到2024年，全球65歲及以上人口的比例將達到10.3%，這意味著需要持續、先進的創傷護理的患者群體正在不斷擴大。

同時，手術部位感染（SSI）的日益增加以及對強力的術後感染控制的需求，正顯著推動市場成長。醫療機構對抗菌敷料的需求不斷成長，這些敷料既能降低外科性創傷的微生物附著量，又能避免傳統銀基療法帶來的細菌抗藥性風險。根據美國疾病管制與預防中心（CDC）於2024年11月發布的《2023年國家和州醫療保健相關感染進展報告》，全子宮切除術後SSI的發生率同比成長8%，凸顯了手術環境中感染預防面臨的持續挑戰。這種臨床上的緊迫性正在推動製造商的商業性成功；例如，康維特集團在2024年報告稱，其先進創傷護理業務在2023會計年度實現了9.5%的有機收入成長，這主要得益於其抗菌產品系列的強勁表現。

市場挑戰

嚴格的監管要求、不一致的報銷政策以及公共醫療體系的預算限制，嚴重阻礙了非銀抗菌敷料市場的發展。這些經濟和監管障礙導致非銀抗菌敷料的臨床療效與商業性可行性之間存在差距。儘管這些替代敷料具有細胞毒性較低等優勢，但由於複雜的報銷機制未能充分反映其高於標準治療產品的初始成本，因此其推廣應用往往受到阻礙。因此，預算固定的醫療機構通常難以證明這些先進解決方案的高價合理，除非能夠獲得全額報銷，否則只能依賴療效較差但價格更低的替代方案。

在對成本高度敏感的市場中，資金籌措差異直接影響籌資策略，這種財務壓力尤其嚴峻。根據歐洲傷口管理協會 (EWMA) 2024 年的報告，一些歐洲國家對先進創傷護理產品的報銷方案通常僅覆蓋總成本的 60% 至 90%，剩餘的費用則由患者或醫療機構承擔。因此，儘管臨床上對非銀基療法的需求十分明確，但由於缺乏全面的報銷方案，採購部門不得不選擇成本較低的傳統敷料，從而限制了市場擴張的潛力。

市場趨勢

重塑市場格局的關鍵趨勢之一是轉型為生物相容性和非細胞毒性材料。醫療保健專業人員越來越重視那些能夠促進傷口癒合且避免長期接觸銀所帶來的細胞毒性風險的解決方案。臨床醫生不再僅僅依賴傳統的殺菌劑，而是轉向使用生物支架和先進基質，這些材料能夠積極促進組織再生並控制微生物附著量。胎盤細胞外基質技術需求的成長清晰地體現了這一轉變，該技術為複雜傷口護理提供了非細胞毒性的選擇。例如，康維特集團在其2025年2月發布的截至2024年12月31日的年度財務報告中指出，其InnovaMatrix平台的收入成長了34%，達到9900萬美元，這印證了臨床實踐正迅速轉向這些生物相容性、非銀基的治療方案。

同時，門診和居家照護專用敷料的推廣應用正推動顯著的商業活動。這主要得益於旨在促進患者早期出院和在院外管理慢性疾病的策略性醫療保健政策。為此，製造商正在開發高度便攜、持久耐用且操作簡便的敷料系統，供看護者和患者在非臨床環境中使用。隨著門診場所逐漸成為初級醫療保健中心，針對適用於門診環境的設計，例如高吸收性泡沫敷料和一次性負壓敷料系統，正帶來顯著的收入成長。根據史密斯醫療（Smith & Nephew）於2025年2月發布的“2024會計年度第四季度及全年業績報告”，該公司高級傷口管理部門第四季度核心收入成長12.2%，創下全年最高業績。這主要得益於適用於長期照護環境的技術的穩步普及。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：非銀抗菌敷料的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美非銀抗菌敷料市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲非銀抗菌敷料市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區非銀抗菌敷料市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲非銀抗菌敷料市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲非銀抗菌敷料市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球非銀抗菌敷料市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Cardinal Health, Inc.
  • Essity AB
  • Winner Medical Co., Ltd.
  • Medline Industries, LP
  • DeRoyal Industries, Inc.
  • Smith & Nephew Plc
  • Advanced Medical Solutions Group plc
  • Organogenesis Inc.
  • Convatec Group Plc
  • Kane Biotech Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 27144

The Global Non-Silver Antimicrobial Dressings Market is projected to expand from USD 494.55 Million in 2025 to USD 629.75 Million by 2031, reflecting a CAGR of 4.11%. These advanced wound care solutions utilize alternative biocidal agents such as iodine, honey, polyhexamethylene biguanide (PHMB), or chlorhexidine to manage infection and bioburden without relying on silver. A major catalyst for this growth is the increasing global prevalence of chronic diseases, particularly diabetes and vascular conditions, which heighten the incidence of hard-to-heal ulcers requiring effective infection control. Additionally, clinical concerns regarding silver resistance and cytotoxicity are encouraging the adoption of these non-silver alternatives. Highlighting the scale of the issue, the International Diabetes Federation reported that approximately 589 million adults were living with diabetes globally in 2024, representing a massive patient population in need of reliable antimicrobial interventions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 494.55 Million
Market Size 2031USD 629.75 Million
CAGR 2026-20314.11%
Fastest Growing Segment
Largest MarketNorth America

Despite this strong demand, the market faces significant hurdles due to stringent regulatory frameworks and inconsistent reimbursement landscapes. Manufacturers are required to navigate complex approval processes that demand substantial clinical evidence to prove the safety and efficacy of these alternative agents against established standards. Furthermore, budgetary limitations within public healthcare systems frequently restrict coverage for these advanced therapies, compelling providers to rely on lower-cost traditional dressings. This economic barrier hampers widespread adoption in cost-sensitive regions, thereby limiting the overall expansion potential of the Global Non-Silver Antimicrobial Dressings Market.

Market Driver

The rapid expansion of the global geriatric population acts as a primary force propelling the adoption of non-silver antimicrobial dressings, given the intrinsic link between aging and susceptibility to chronic wounds. As people age, physiological deterioration, including reduced skin elasticity and compromised immune responses, significantly elevates the risk of difficult-to-treat conditions such as pressure injuries and venous leg ulcers. These chronic issues often necessitate prolonged infection management, where alternative agents like medical honey or PHMB are favored over silver to circumvent potential issues with cytotoxicity and resistance. Underscoring this demographic shift, the United Nations Population Fund's June 2024 'Ageing' report noted that the global share of individuals aged 65 and older rose to 10.3% in 2024, confirming an expanding patient pool that requires sustained advanced wound care.

In parallel, the increasing prevalence of surgical site infections (SSIs) and the imperative for robust post-operative infection control are substantially fueling market growth. Healthcare institutions are actively seeking antimicrobial dressings capable of reducing bioburden in surgical wounds while avoiding the bacterial resistance risks associated with traditional silver therapies. According to the Centers for Disease Control and Prevention's '2023 National and State Healthcare-Associated Infections Progress Report' released in November 2024, SSIs following abdominal hysterectomies rose by 8% over the prior year, emphasizing the ongoing struggle with infection prevention in surgical environments. This clinical urgency is driving commercial success for manufacturers; for instance, Convatec Group Plc reported in 2024 that its Advanced Wound Care business achieved 9.5% organic revenue growth for fiscal year 2023, largely attributed to the strong performance of its antimicrobial portfolios.

Market Challenge

The market is significantly impeded by a combination of strict regulatory requirements, inconsistent reimbursement policies, and budgetary constraints within public healthcare systems. These economic and regulatory barriers create a disconnect between the clinical efficacy of non-silver antimicrobial dressings and their commercial viability. Although these alternatives offer benefits such as reduced cytotoxicity, their uptake is often hindered by complex reimbursement structures that do not adequately factor in their higher upfront costs compared to standard-of-care products. Consequently, healthcare providers operating under fixed budgets frequently find it difficult to justify the premium pricing of these advanced solutions without guaranteed full coverage, leading them to rely on less effective, cheaper options.

This financial pressure is particularly severe in cost-sensitive markets where gaps in funding directly influence procurement strategies. According to the European Wound Management Association in 2024, reimbursement mechanisms for advanced wound care products in select European countries typically covered only 60% to 90% of the total cost, forcing patients or institutions to absorb the remaining financial burden. As a result, despite the clear clinical demand for non-silver therapies, the absence of comprehensive reimbursement forces procurement departments to default to lower-cost traditional dressings, thereby restricting the market's potential for expansion.

Market Trends

A significant trend reshaping the market is the shift toward biocompatible and non-cytotoxic material profiles, as healthcare professionals increasingly prioritize solutions that facilitate healing without the cellular toxicity risks linked to prolonged silver exposure. Clinicians are moving toward biologic scaffolds and advanced matrices that manage bioburden while actively promoting tissue regeneration, rather than depending solely on traditional biocidal agents. This evolution is highlighted by the rising demand for placental extracellular matrix technologies, which provide a non-cytotoxic option for treating complex wounds. For example, Convatec Group reported in February 2025 within its 'Annual Results for the year ended 31 December 2024' that revenue for its InnovaMatrix platform surged by 34% to $99 million, underscoring the rapid clinical transition toward these biocompatible, non-silver therapeutic options.

Concurrently, the expansion of specialized dressings for ambulatory and home care settings is driving substantial commercial activity, motivated by strategic healthcare initiatives to discharge patients earlier and manage chronic conditions outside of hospitals. Manufacturers are responding by engineering portable, long-wear, and intuitive dressing systems tailored for use by caregivers or patients in non-clinical environments. This emphasis on ambulatory-friendly designs, such as high-absorbency foams and single-use negative pressure systems, is generating significant revenue growth as these settings become primary care locations. According to Smith+Nephew's 'Fourth Quarter and Full Year 2024 Results' published in February 2025, their Advanced Wound Management unit achieved 12.2% underlying revenue growth in the fourth quarter-its strongest yearly performance-driven largely by the robust adoption of technologies suited for extended care settings.

Key Market Players

  • Cardinal Health, Inc.
  • Essity AB
  • Winner Medical Co., Ltd.
  • Medline Industries, LP
  • DeRoyal Industries, Inc.
  • Smith & Nephew Plc
  • Advanced Medical Solutions Group plc
  • Organogenesis Inc.
  • Convatec Group Plc
  • Kane Biotech Inc.

Report Scope

In this report, the Global Non-Silver Antimicrobial Dressings Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Non-Silver Antimicrobial Dressings Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Non-Silver Antimicrobial Dressings Market.

Available Customizations:

Global Non-Silver Antimicrobial Dressings Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Non-Silver Antimicrobial Dressings Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Region
    • 5.2.2. By Company (2025)
  • 5.3. Market Map

6. North America Non-Silver Antimicrobial Dressings Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Non-Silver Antimicrobial Dressings Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
    • 6.3.2. Canada Non-Silver Antimicrobial Dressings Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
    • 6.3.3. Mexico Non-Silver Antimicrobial Dressings Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast

7. Europe Non-Silver Antimicrobial Dressings Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Non-Silver Antimicrobial Dressings Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
    • 7.3.2. France Non-Silver Antimicrobial Dressings Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
    • 7.3.3. United Kingdom Non-Silver Antimicrobial Dressings Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
    • 7.3.4. Italy Non-Silver Antimicrobial Dressings Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
    • 7.3.5. Spain Non-Silver Antimicrobial Dressings Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast

8. Asia Pacific Non-Silver Antimicrobial Dressings Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Non-Silver Antimicrobial Dressings Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
    • 8.3.2. India Non-Silver Antimicrobial Dressings Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
    • 8.3.3. Japan Non-Silver Antimicrobial Dressings Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
    • 8.3.4. South Korea Non-Silver Antimicrobial Dressings Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
    • 8.3.5. Australia Non-Silver Antimicrobial Dressings Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast

9. Middle East & Africa Non-Silver Antimicrobial Dressings Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Non-Silver Antimicrobial Dressings Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
    • 9.3.2. UAE Non-Silver Antimicrobial Dressings Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
    • 9.3.3. South Africa Non-Silver Antimicrobial Dressings Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast

10. South America Non-Silver Antimicrobial Dressings Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Non-Silver Antimicrobial Dressings Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
    • 10.3.2. Colombia Non-Silver Antimicrobial Dressings Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
    • 10.3.3. Argentina Non-Silver Antimicrobial Dressings Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Non-Silver Antimicrobial Dressings Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Cardinal Health, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Essity AB
  • 15.3. Winner Medical Co., Ltd.
  • 15.4. Medline Industries, LP
  • 15.5. DeRoyal Industries, Inc.
  • 15.6. Smith & Nephew Plc
  • 15.7. Advanced Medical Solutions Group plc
  • 15.8. Organogenesis Inc.
  • 15.9. Convatec Group Plc
  • 15.10. Kane Biotech Inc.

16. Strategic Recommendations

17. About Us & Disclaimer